This HTML5 document contains 22 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n8	http://linked.opendata.cz/resource/mesh/concept/
rdfs	http://www.w3.org/2000/01/rdf-schema#
n5	http://linked.opendata.cz/resource/fda-spl/ingredient/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n7	http://linked.opendata.cz/ontology/mesh/
owl	http://www.w3.org/2002/07/owl#
nci	http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
n6	http://linked.opendata.cz/resource/ndfrt/ingredient/
xsdh	http://www.w3.org/2001/XMLSchema#

Statements

Subject Item

nci:C29071

rdf:type

owl:Class

rdfs:label

Gemfibrozil

rdfs:subClassOf

nci:C98150

nci:A8

nci:C63923

nci:P106

Pharmacologic Substance

nci:P108

Gemfibrozil

nci:P207

C0017245

nci:P210

25812-30-0

nci:P319

Q8X02027X3

nci:P322

FDA

nci:P350

C15H22O3

nci:P366

Gemfibrozil

nci:P368

CHEBI:5296

nci:P90

<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Lopid</n0:term-name><n0:term-group>BR</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Gemfibrozil</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>DCP</n0:term-source><n0:source-code>06549</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Gemfibrozil</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>GEMFIBROZIL</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>Q8X02027X3</n0:source-code></n0:ComplexTerm>

nci:P97

<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A fibric acid derivative with hypolipidemic effects. Gemfibrozil interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III results in subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C).</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>

nci:code

C29071

owl:sameAs

n5:Q8X02027X3 n6:N0000007039

n7:hasConcept

n8:M0023484